Sun Pharma Advanced Research Company Ltd Sees Mixed Technical Signals Amid Price Momentum Shift

Price Momentum and Recent Performance

SPARC closed at ₹133.45 on 2 Feb 2026, marking a significant 5.66% increase from the previous close of ₹126.30. The stock’s intraday range spanned ₹126.90 to ₹141.95, indicating heightened volatility and buying interest. However, this rally comes against a backdrop of longer-term underperformance relative to the benchmark Sensex. Over the past year, SPARC has declined by 15.54%, while the Sensex gained 5.16%. The disparity widens over extended periods, with SPARC down 30.68% over three years and 56.89% over ten years, contrasting sharply with the Sensex’s robust gains of 35.67% and 224.57% respectively.

Technical Trend Shift: From Bearish to Mildly Bearish

The technical trend for SPARC has recently shifted from a firmly bearish stance to a mildly bearish one. This subtle improvement is reflected in several indicators, though the overall tone remains cautious. The daily moving averages continue to signal bearish momentum, with the stock trading below key averages, suggesting resistance to sustained upward movement. Meanwhile, the weekly and monthly Bollinger Bands also indicate mild bearishness, highlighting that price volatility remains skewed towards downside risk despite recent gains.

MACD and RSI Analysis

The Moving Average Convergence Divergence (MACD) remains bearish on both weekly and monthly timeframes, signalling that the underlying momentum is still weak. The MACD line continues to stay below the signal line, indicating that the recent price uptick may lack strong follow-through. Relative Strength Index (RSI) readings on weekly and monthly charts show no clear signal, hovering in neutral zones without reaching oversold or overbought extremes. This absence of RSI confirmation tempers enthusiasm for a sustained rally, suggesting that the stock is consolidating rather than trending decisively.

Moving Averages and KST Indicator

Daily moving averages remain bearish, with the stock price below the 50-day and 200-day averages, signalling persistent downward pressure. However, the Know Sure Thing (KST) indicator presents a more optimistic picture, showing mildly bullish signals on both weekly and monthly charts. This divergence suggests that while short-term momentum is weak, there may be emerging signs of a potential trend reversal or at least a pause in the downtrend.

Dow Theory and On-Balance Volume (OBV)

Dow Theory assessments are mixed: weekly readings are mildly bullish, indicating some optimism among traders, but monthly readings remain mildly bearish, reflecting longer-term caution. On-Balance Volume (OBV) shows no clear trend on either weekly or monthly timeframes, implying that volume flows have not decisively supported either buying or selling pressure. This lack of volume confirmation further complicates the outlook, as price moves without volume backing tend to be less sustainable.

Valuation and Market Capitalisation Context

SPARC’s market capitalisation grade stands at 3, reflecting a mid-tier valuation within its sector. The company’s Mojo Score of 6.0 and a recent downgrade from Sell to Strong Sell on 1 Feb 2024 underscore the cautious stance adopted by analysts. This downgrade reflects concerns over the company’s fundamentals and technical outlook, despite the recent price bounce. Investors should weigh these factors carefully, especially given the stock’s significant underperformance relative to the broader market indices.

Comparative Returns and Sector Performance

When compared to the Sensex, SPARC’s returns have lagged considerably across all measured periods. The stock’s one-week return of 7.06% outperformed the Sensex’s -1.00%, indicating short-term strength. However, this is offset by negative returns over one month (-0.74% vs. Sensex -4.67%) and year-to-date (-0.74% vs. Sensex -5.28%). Over longer horizons, the stock’s underperformance is stark, with losses exceeding 15% over one year and over 25% across five years, while the Sensex has delivered positive returns consistently. This divergence highlights the challenges SPARC faces in regaining investor confidence and market share within the Pharmaceuticals & Biotechnology sector.

Investor Takeaway and Outlook

SPARC’s recent price momentum shift and mixed technical signals present a challenging environment for investors. While the intraday rally and mildly bullish KST and Dow Theory weekly signals offer some hope for a recovery, the prevailing bearish MACD, daily moving averages, and lack of volume confirmation suggest caution. The stock’s significant underperformance relative to the Sensex and its downgrade to a Strong Sell rating further reinforce the need for prudence.

Investors should monitor key technical levels closely, particularly the ability of SPARC to sustain prices above the 50-day moving average and break out of the Bollinger Bands’ mildly bearish range. Confirmation from momentum indicators such as MACD turning positive and RSI moving into bullish territory would be necessary to signal a more durable trend reversal. Until then, the stock remains vulnerable to downside risks amid sector headwinds and valuation concerns.

Conclusion

Sun Pharma Advanced Research Company Ltd’s technical landscape is characterised by a tentative shift from bearish to mildly bearish, with mixed signals across momentum and volume indicators. The stock’s recent price gains are encouraging but require confirmation through sustained technical improvements and fundamental support. Given the current Strong Sell rating and relative underperformance, investors should approach SPARC with caution and consider alternative opportunities within the Pharmaceuticals & Biotechnology sector that demonstrate stronger momentum and valuation metrics.

Unlock special upgrade rates for a limited period. Start Saving Now →